Sun Pharma - Concert Deal Paves Way To Add JAK Inhibitors To Specialty Portfolio: Motilal Oswal
Adds Deuroxolitinib, a potential best-in-class JAK inhibitor, to its specialty portfolio through acquisition of Concert Pharma Inc
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Sun Pharmaceutical Industries Ltd. adds Deuroxolitinib, a potential best-in-class JAK inhibitor, to its specialty portfolio through the acquisition of Concert Pharma Inc.
Deuroxolitnib has shown a better Severity of Alopecia Tool score compared to peers, providing confidence on the potential of the product post regulatory approval.
The deal further enhances specialty offerings by Sun Pharma in the dermatology space.
The development potential of concert synergises with marketing capabilities of Sun Pharma, thereby aiding significant value accretion on the combined basis.
We maintain our estimates given that the products are under development. We remain positive on Sun Pharma, considering its effort to strengthen the specialty franchise, branded generics led growth in India/emerging/rest of world market, and its robust abbreviated new drug application pipeline for the U.S. market.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.